Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. The company’s breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug, and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information, visit the company’s website at www.ocugen.com
To watch the presentation, visit https://ibn.fm/NobleCon17Registration
To view IBN’s virtual coverage of Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, visit https://ibn.fm/NobleCon17
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN used social media and syndicated articles to maximize the visibility of NobleCon17.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com